268 related articles for article (PubMed ID: 31271486)
41. The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison.
Cowell IG; Ling EM; Swan RL; Brooks MLW; Austin CA
Mol Pharmacol; 2019 Nov; 96(5):562-572. PubMed ID: 31515282
[TBL] [Abstract][Full Text] [Related]
42. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
43. Differentiated and exponentially growing HL60 cells exhibit different sensitivity to some genotoxic agents in the comet assay.
Montag G; Bankoglu EE; Bolte A; Hintzsche H; Djelic N; Stopper H
Mutat Res Genet Toxicol Environ Mutagen; 2019 Sep; 845():402972. PubMed ID: 31561892
[TBL] [Abstract][Full Text] [Related]
44. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
[TBL] [Abstract][Full Text] [Related]
45. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
46. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
47. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
Wang L; Roy SK; Eastmond DA
Mutat Res; 2007 Mar; 616(1-2):70-82. PubMed ID: 17174356
[TBL] [Abstract][Full Text] [Related]
48. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
[TBL] [Abstract][Full Text] [Related]
49. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
50. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
51. The Impact of the C-Terminal Region on the Interaction of Topoisomerase II Alpha with Mitotic Chromatin.
Antoniou-Kourounioti M; Mimmack ML; Porter ACG; Farr CJ
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871006
[TBL] [Abstract][Full Text] [Related]
52. N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison.
Bender RP; Lindsey RH; Burden DA; Osheroff N
Biochemistry; 2004 Mar; 43(12):3731-9. PubMed ID: 15035644
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage.
Barker CR; McNamara AV; Rackstraw SA; Nelson DE; White MR; Watson AJ; Jenkins JR
Nucleic Acids Res; 2006; 34(4):1148-57. PubMed ID: 16504968
[TBL] [Abstract][Full Text] [Related]
54. Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.
Sonabend AM; Carminucci AS; Amendolara B; Bansal M; Leung R; Lei L; Realubit R; Li H; Karan C; Yun J; Showers C; Rothcock R; O J; Califano A; Canoll P; Bruce JN
Neuro Oncol; 2014 Sep; 16(9):1210-9. PubMed ID: 24637229
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines.
Shrestha A; Park S; Shin S; Man Kadayat T; Bist G; Katila P; Kwon Y; Lee ES
Bioorg Chem; 2018 Sep; 79():1-18. PubMed ID: 29715635
[TBL] [Abstract][Full Text] [Related]
56. FEN1 participates in repair of the 5'-phosphotyrosyl terminus of DNA single-strand breaks.
Kametani Y; Takahata C; Narita T; Tanaka K; Iwai S; Kuraoka I
Carcinogenesis; 2016 Jan; 37(1):56-62. PubMed ID: 26581212
[TBL] [Abstract][Full Text] [Related]
57. Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
Laev SS; Salakhutdinov NF; Lavrik OI
Bioorg Med Chem; 2016 Nov; 24(21):5017-5027. PubMed ID: 27687971
[TBL] [Abstract][Full Text] [Related]
58. Nanoscale Assembly of High-Mobility Group AT-Hook 2 Protein with DNA Replication Fork.
Krahn N; Meier M; To V; Booy EP; McEleney K; O'Neil JD; McKenna SA; Patel TR; Stetefeld J
Biophys J; 2017 Dec; 113(12):2609-2620. PubMed ID: 29262356
[TBL] [Abstract][Full Text] [Related]
59. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
60. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]